Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

"Mannkind, "MNKD", Has the Potential to Be the Next HGSI"

Checkout HGSI’s price performance after it entered into a development partnership agreement with GlaxoSmithKlein.

finance.yahoo.com/q/bc?s=HGSI&t=2y&a...=


HGSI’s current market cap is $5,560,000,000 and it has yet to produce any sales.

It is my belief that Mannkind will soon announce a pipeline development partnership with a company such as Sanof-Aventis with the opportunity for a similar share price appreciation over the next two years.

Mannkind is one of about five companies that have potential blockbuster drugs in late stage development where the company is a legitimate takeover or partnership candidate. Big phama is faced with losing over $100 billion in revenues over the next three years due to drugs going "off-patent".

Mannkind’s Product Pipeline: Overview

MannKind Corporation’s research pipeline includes products for diabetes and cancer. AFREZZA® (pronounced uh-FREZZ-uh) is a novel, ultra rapid-acting mealtime insulin therapy in late stage clinical investigation for the treatment of adult patients with Type 1 and Type 2 diabetes mellitus for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA inhalation powder pre-metered into single use dose cartridges and the light, discreet and easy-to-use AFREZZA inhaler.  Because of its unique pharmacokinetic profile, AFREZZA may be a promising new therapy for patients with Type 1 and Type 2 diabetes, as it controls post meal-time glucose levels with less weight gain and lower risk of hypoglycemia.


MKC253 is a Technosphere formulation of GLP-1 (glucagon-like peptide). In initial clinical studies, MKC253 showed a lack of the characteristic adverse events, like nausea and vomiting, that are frequently associated with long-acting GLP-1 analogs. Results from a phase 1 trial supported the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with Type 2 diabetes.


MKC1106 is MannKind’s active immunotherapy platform, and there are three separate programs. MKC1106-PP, designed to target solid tumors, completed an open label phase 1 clinical trial and objective responses were observed in prostate cancer and renal cell carcinoma. MKC1106-MT is now being evaluated in a phase 2 clinical trial for patients with advanced melanoma. MKC1106-NS may be applicable to a range of solid and blood cancers.

MKC204 is an IRE-1 alpha inhibitor with potential application in the treatment of multiple myeloma. IRE-1 alpha is a protein important in the regulation of the Unfolded Protein Response (UPR) cascade.Additional potential indications for UPR pathway inhibitors include autoimmune diseases, cardiovascular diseases and neurodegenerative disorders.



Disclosure: I am long MNKD.